Wednesday, 15 July 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 15 July 2026
News

Wave of rare disease drugs hit TGA

Posted 14 July 2026 PM

A new wave of treatments for rare diseases are on the cusp of being filed with the TGA after receiving orphan status.

Over the past two months, Australia’s medicines regulator granted seven orphan drug designations, two of which were given to Lacuna Pharma’s methotrexate oral solution for the treatment of acute lymphoblastic leukaemia plus for the treatment of polyarticular juvenile idiopathic arthritis in paediatric patients.

To see the whole article, please login

Popular

Ex-J&J leader lands CEO role
Novartis settles case with Zeller
Butler fires a delisting warning shot
Who's bested two Big Pharmas?
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (23)

Access & Reimbursement (1)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (3)

Other (10)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home